益方生物(688382)立足未满足需求，专注高门槛靶向药开发

东方证券08-01

核心观点专注肿瘤和自免，进攻高门槛靶向药的Biotech。公司由王耀林等多位海归博士联合创办，核心团队均具备医学或药学背景，学术背景雄厚，产业经验丰富。目前，公司共有5款处于临床试验或已上市阶段的品种，包括三代EGFRTKI、KRASG12C抑制剂和口服SERD等高门槛药物，覆盖肿瘤和自免代谢两大领域的大适应症。其中，1款已获批上市，4款处于临床试验阶段，并与贝达药业、正大天晴、辉瑞和默沙东等...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2456214874?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-01 09:17","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2456214874","market":"sh","top_or_hot":-1,"title":"益方生物(688382)立足未满足需求，专注高门槛靶向药开发","media":"东方证券","content":"<div>\n<p>核心观点专注肿瘤和自免，进攻高门槛靶向药的Biotech。公司由王耀林等多位海归博士联合创办，核心团队均具备医学或药学背景，学术背景雄厚，产业经验丰富。目前，公司共有5款处于临床试验或已上市阶段的品种，包括三代EGFRTKI、KRASG12C抑制剂和口服SERD等高门槛药物，覆盖肿瘤和自免代谢两大领域的大适应症。其中，1款已获批上市，4款处于临床试验阶段，并与 贝达药业 、正大天晴、辉瑞和默沙东等...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408010959309572f67b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>益方生物(688382)立足未满足需求，专注高门槛靶向药开发</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n益方生物(688382)立足未满足需求，专注高门槛靶向药开发\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-01 09:17 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408010959309572f67b&s=b><strong>东方证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>核心观点专注肿瘤和自免，进攻高门槛靶向药的Biotech。公司由王耀林等多位海归博士联合创办，核心团队均具备医学或药学背景，学术背景雄厚，产业经验丰富。目前，公司共有5款处于临床试验或已上市阶段的品种，包括三代EGFRTKI、KRASG12C抑制剂和口服SERD等高门槛药物，覆盖肿瘤和自免代谢两大领域的大适应症。其中，1款已获批上市，4款处于临床试验阶段，并与 贝达药业 、正大天晴、辉瑞和默沙东等...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408010959309572f67b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408010959309572f67b&s=b","article_id":"2456214874","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408010959309572f67b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2456214874","pubTimestamp":1722475042,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"核心观点专注肿瘤和自免，进攻高门槛靶向药的Biotech。目前，公司共有5款处于临床试验或已上市阶段的品种，包括三代EGFRTKI、KRASG12C抑制剂和口服SERD等高门槛药物，覆盖肿瘤和自免代谢两大领域的大适应症。目前，国内尚无KRASG12C抑制剂获批上市，格舒瑞昔有望成为国内首个获批产品；D-0502是公司开发的口服SERD，目前国内尚无同类产品获批上市。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688382":"益方生物","BK0239":"医药制造"},"translate_title":"Yifang Biotech (688382) is based on unmet needs and focuses on the development of high-threshold targeted drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688382":1},"content_text":"核心观点专注肿瘤和自免，进攻高门槛靶向药的Biotech。公司由王耀林等多位海归博士联合创办，核心团队均具备医学或药学背景，学术背景雄厚，产业经验丰富。目前，公司共有5款处于临床试验或已上市阶段的品种，包括三代EGFRTKI、KRASG12C抑制剂和口服SERD等高门槛药物，覆盖肿瘤和自免代谢两大领域的大适应症。其中，1款已获批上市，4款处于临床试验阶段，并与 贝达药业 、正大天晴、辉瑞和默沙东等国内外知名药企达成合作；肿瘤领域：瞄准高难靶点，布局需求急迫的大适应症。公司和贝达药业合作的贝福替尼已获批上市，用于晚期EGFR突变NSCLC(非小细胞肺癌)患者的一线和二线治疗，相较同类产品在生存数据及颅内疗效具有优势，此外辅助治疗适应症正处于临床III期阶段；公司和正大天晴合作的格舒瑞昔为KRASG12C抑制剂，针对该靶点突变晚期NSCLC二线治疗已递交NDA，有望年内获批。KRASG12C突变的NSCLC的一线治疗、CRC(结直肠癌)和PC(胰腺癌)均处于II期临床试验阶段。目前，国内尚无KRASG12C抑制剂获批上市，格舒瑞昔有望成为国内首个获批产品；D-0502是公司开发的口服SERD，目前国内尚无同类产品获批上市。D-0502处于临床III期阶段，是国内进度最快的口服SERD；自免代谢：国内进度靠前，瞄准两大百亿市场。公司目前布局有URAT1抑制剂D-0120和TYK2抑制剂D-2570，分别用于高尿酸血症、痛风和银屑病的治疗，皆为国内患病率高、市场庞大且临床未满足需求高的适应症。从开发进度看，公司产品在国产药物中都位于第一/二梯队。盈利预测与投资建议我们预测公司2024-2026年归母净利润分别为-3.10、-2.26、-3.37亿元，对公司自由现金流进行绝对估值，预测公司合理市值为50.46亿元，对应目标价为8.75元，首次给予“买入”评级。风险提示创新药研发进度不及预期、产品竞争加剧导致销售不及预期、公司中长期盈利能力下降的风险等。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2456214874"}